Therefore, these results suggest that NAC sensitivity was decreased in tumors with high expression of GR, Sgk1, and NDRG1, resulting in higher residual tumor cells and subsequent adverse clinical outcomes of patients. The gene discussed is NDRG1; the disease is neoplasm.